Moxifloxacin in the treatment of skin and skin structure infections

David RP Guay
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA

Abstract: Moxifloxacin is a recent addition to the fluoroquinolone class, differing from ciprofloxacin and other older agents in having much better in vitro activity against Gram-positive aerobes while retaining potent activity against Gram-negative aerobes. It is also active against the pathogens of human and animal bite wounds and those species of atypical mycobacteria associated with dermatologic infections. Its activity against anaerobes is quite variable. Moxifloxacin penetrates well into inflammatory blister fluid and muscle and subcutaneous adipose tissues. Moxifloxacin should thus be a reasonable option for the treatment of skin and skin structure infections (SSSIs). In 3 randomized controlled trials (RCTs), oral moxifloxacin was as effective as cephalexin in the treatment of uncomplicated SSSIs in adults while in 2 RCTs, intravenous/oral moxifloxacin was as effective as intravenous/oral β-lactam/β-lactamase inhibitor therapy in the treatment of complicated SSSIs in adults. Moxifloxacin does not inhibit cytochrome P450 enzymes and thus interact with warfarin or methylxanthines. However, multivalent cations can reduce its oral bioavailability substantially. Dosage adjustment is not required in the presence of renal or hepatic impairment. The clinical relevance of its electrophysiologic effects (QTc prolongation) remains unresolved.

Keywords: moxifloxacin, skin infections, fluoroquinolones, skin ulcers, cellulitis

Introduction

Moxifloxacin is one of most-recently marketed of the fluoroquinolone (hereafter called quinolone) antimicrobials (Avelox®, Bayer, Leverkusen, Germany). Of this group (gatifloxacin, gemifloxacin, moxifloxacin), only moxifloxacin has regulatory approval for use in skin and skin structure infections (SSSIs) (Anonymous 2005). Until recently, this approval was limited to uncomplicated SSSIs in adults caused by Staphylococcus aureus or Streptococcus pyogenes (Anonymous 2005). In June of 2005, it also received approval for use in complicated SSSIs caused by methicillin-susceptible S. aureus, Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae (Anonymous 2005). Complicated SSSIs are defined as those which involve deeper layers such as fascia or muscle, require significant surgical interventions, or arise in the presence of significant comorbidities such as diabetes or HIV infection (Raghavan and Linden 2004). The purpose of this paper is to review the in vitro antimicrobial activity, pharmacokinetics, clinical and bacteriological efficacy, safety, tolerability, and drug–drug interaction potential of moxifloxacin, concentrating on its potential role in the treatment of complicated (and uncomplicated) SSSIs.

Mechanisms of action and resistance

Moxifloxacin acts by the same mechanism as other quinolones: inhibition of bacterial DNA gyrase (a Type II topoisomerase composed of two gyrA and two gyrB subunits) and topoisomerase IV (a heterotetramer made up of two parC and two parE subunits (Ruiz 2003; Mitscher 2005). Topoisomerase IV is felt to be the preferred target, especially in Gram-positive aerobes (Ince et al 2003). Resistance is mediated in all
quinolones by either changes in the target site (DNA gyrase and/or topoisomerase IV) or changes that alter intracellular drug accumulation (ie, enhanced efflux).

In vitro antimicrobial activity

Unlike earlier quinolones like ciprofloxacin, moxifloxacin has significant activity against Gram-positive aerobes, including potential dermatologic pathogens such as *S. aureus*, coagulase-negative staphylococci, and groups A/F/C/G streptococci (Table 1) (Dalhoff et al 1996; Bauernfeind 1997; Goldstein et al 1997; Omer et al 2000; Woodcock et al 1997; Barry et al 1999; Malathum et al 1999; von Eiff et al 1999; Blondeau et al 2000; Fass 1997; Goldstein et al 1997; MacGowen et al 1997; Woodcock et al 1997; Barry et al 1999; Malathum et al 1999; von Eiff et al 1999; Blondeau et al 2000; Hoogkamp-Korstanje et al 2000; Milatovic et al 2000; Amabile-Cuevas et al 2001; Blondeau et al 2002; Speciale et al 2002; Bowker et al 2003; Hsueh et al 2003; Noviello et al 2003; Edmiston et al 2004; Patel et al 2004; Wenzler et al 2004; Bogdanovich et al 2005; Stratchounski et al 2005). Methicillin-resistant strains of staphylococci are much less susceptible and enterococci are only moderately susceptible to moxifloxacin. Moxifloxacin still retains significant activity against Gram-negative aerobes with the exception of variable activity against *Pseudomonas aeruginosa*, other pseudomonads, and *Stenotrophomonas maltophilia* (Table 1). Among anaerobes, moxifloxacin is quite active against the majority of pathogens of animal and human bite wounds. Activity against *Bacteroides*, *Fusobacterium*, and *Prevotella* species is variable (Table 2) (Dalhoff et al 1996; Aldridge and Ashcraft 1997; Bauernfeind 1997; Fass 1997; Goldstein et al 1997; MacGowen et al 1997; Bauernfeind 1997; Fass 1997; Goldstein et al 2000, 2002, 2006; Hoogkamp-Korstanje et al 2000; Milatovic et al 2000; Schaumann et al 2000; Hoellman et al 2001; Snydman et al 2002; Speciale et al 2002; Eduard et al 2003; Hedberg et al 2003; Edmiston et al 2004, 2005; Peric et al 2004; Sillerstrom et al 2004; Lion et al 2006).

Moxifloxacin has significant activity against many strains of atypical mycobacteria, microorganisms of significance in dermatological infections. For example, the following minimum inhibitory concentrations of 90% of isolates (MIC90) values (in mg/L) have been reported for a) *Mycobacterium marinum*, b) *M. fortuitum*, c) *M. chelonae*, d) *M. abscessus*, e) *M. kansasi*, and f) *M. gordonae*: a) 8.0 (43 isolates) (Braback et al 2002), 1.0 (53 isolates) (Aubry et al 2000); b) 16.0 (69 isolates) (Yang et al 2000), 1.0 (7

| Organism | Isolates (n) | Range of MIC90 (mg/L) | References |
|----------|--------------|-----------------------|------------|
| *Staphylococcus aureus* | 1427 | 0.03–>4.0 | (1–6) |
| methicillin-sensitive | 1221 | 0.06–4.0 | (7–21, 27) |
| methicillin-resistant | 1036 | 2–16 | (2, 7–12, 14–21) |
| *S. epidermidis* | 183 | 0.06–4.0 | (3, 5, 18, 20) |
| methicillin-sensitive | 424 | 0.06–2.0 | (9–12, 15–17, 19, 22) |
| methicillin-resistant | 641 | 0.12–>8.0 | (9–12, 14–17, 19, 27) |
| Group A streptococci | 1882 | 0.12–0.50 | (2.6–9.11, 13.15, 18–20, 23–25) |
| Group B streptococci | 139 | 0.12–0.50 | (6, 9, 11, 15, 18, 19, 23) |
| *Enterococcus faecalis* | 438 | 0.25–16 | (2, 6, 9, 11, 13–15, 18–23, 27) |
| *E. faecium* | 263 | 2–>32 | (6, 9, 11, 13–15, 18, 20, 23, 27) |
| *Escherichia coli* | 795 | 0.015–1.0 | (2, 13–16, 18, 19, 22, 26, 27) |
| *Klebsiella pneumoniae* | 619 | 0.031–1.0 | (2, 14–16, 18, 19, 27) |
| *Citrobacter freundii* | 290 | 1–4 | (11, 14–16, 18, 19, 22, 27) |
| *Morganella morganii* | 248 | 0.13–16 | (11, 14–16, 18–20) |
| *Proteus mirabilis* | 530 | 0.25–16 | (2, 11, 14–16, 18–22, 27) |
| *Enterobacter cloacae* | 541 | 0.06–2 | (11, 14–16, 18, 19, 27) |
| *E. aerogenes* | 325 | 0.5–>16 | (11, 14–16, 18, 19, 27) |
| *Pseudomonas aeruginosa* | 2376 | 4–64 | (2, 11, 13, 15, 16, 18–22, 27) |
| *P. vulgaris* | 141 | 0.25–1 | (11, 15, 16, 18, 20, 22) |
| *Acinetobacter calcoaceticus* | 60 | 0.06–1 | (2, 11, 22) |

Abbreviations: MIC90, minimum inhibitory concentration for 90% of isolates.

Note: For entries with multiple studies, data are the range. To be included, studies had to have a minimum of 10 isolates of the microorganism-of-interest, use a National Committee for Clinical Laboratory Standards - approved methodology, and an inoculum of 10^5–10^6 organisms.

References: 1, Stratchounski et al 2005; 2, Blondeau et al 2000; 3, Jacobs et al 2004; 4, Goldstein et al 2000; 5, Goldstein et al 1997; 6, Malathum et al 1999; 7, Bowker et al 2003; 8, Noviello et al 2003; 9, Speciale et al 2002; 10, von Eiff et al 1999; 11, Bauernfeind 1997; 12, Patet et al 2004; 13, Wenzler et al 2004; 14, Edmiston et al 2004; 15, Fung-Tome et al 2000; 16, Milatovic et al 2000; 17, Hardy et al 2000; 18, Barry et al 1999; 19, Fass 1997; 20, Woodcock et al 1997; 21, Bogdanovich et al 2005; 22, Dalhoff et al 1996; 23, Hoogkamp-Korstanje et al 2000; 24, Hoogkamp-Korstanje et al 2000; 25, Amabile-Cuevas et al 2001; 26, Blondeau et al 2002; 27, Edmiston et al 2005.
Moxifloxacin in skin infections

Isolates (Gillespie and Billington 1999), 0.5 (16 isolates) (Rodriguez Diaz et al 2003); c) 8.0 (39 isolates) (Yang et al 2003), 16.0 (4 isolates) (Rodriguez Diaz et al 2003); d) 16.0 (92 isolates) (Yang et al 2003); e) 0.06 (16 isolates) (Gillespie and Billington 1999), 0.06 (148 isolates) (Alcaide et al 2004), 2.0 (8 isolates) (Rodriguez Diaz et al 2003); f) 0.5 (23 isolates) (Rodriguez Diaz et al 2003).

Important microorganisms in the context of skin and skin structure infections related to foreign devices are the coagulase-negative staphylococci (CNS), especially those strains able to produce biofilm (an extracellular glycocalyx material also called “slime”). Moxifloxacin’s activity has been evaluated in vitro against 19 biofilm-producing (MIC<sub>90</sub> = 2 mg/L) and 22 biofilm-nonproducing (MIC<sub>90</sub> = 0.25 mg/L) strains of CNS. SubMIC concentrations of moxifloxacin did not modify biofilm production. It had poor activity against stationary phase microorganisms but had some activity against microorganisms in the biofilm. However, high drug concentrations were necessary for this activity (50- and 100-fold MIC concentrations produced mean 1.10 and 1.69 log reductions in bacterial counts, respectively) (Perez-Giraldo et al 2004). In these regards, moxifloxacin unfortunately behaved like many other antimicrobials evaluated previously.

In another study with potential application to foreign device-related infections, an in vitro study was performed evaluating the bactericidal activity of moxifloxacin monotherapy and combination moxifloxacin plus vancomycin/teicoplanin therapy in 9 S. aureus isolates (1 being methicillin- and quinolone-sensitive and 8 being resistant to both). These isolates came from patients unresponsive to glycopeptide therapy or relapsing after completion of glycopeptide therapy despite device removal. Moxifloxacin MICs were 0.125 mg/L (in the 1 methicillin-sensitive isolate) and 2.0 mg/L (in all of the methicillin-resistant isolates). All isolates were tolerant to vancomycin, teicoplanin, and moxifloxacin at medium concentrations 2 X MIC. However, moxifloxacin plus glycopeptide combination therapy was bactericidal at the glycopeptide MIC and 0.5 X MIC of moxifloxacin (Tarasi et al 2003). Thus, combination therapy may be worthwhile considering in difficult-to-treat patients.

Characteristic of quinolones, moxifloxacin has concentration-dependent bactericidal activity (Dalhoff et al 1996). This has been shown with methicillin-sensitive and -resistant S. aureus and coagulase-negative staphylococci (Lister 2001, Speciale et al 2002; Noviello et al 2003; Bogdanovich et al 2005), S. pyogenes (Esposito et al 2000;
Odenholt et al 2002; Speciale et al 2002; Noviello et al 2003), Enterococcus faecalis (Speciale et al 2002), and a variety of anaerobes (Credito et al 2003). Bactericidal activity using serum bactericidal titer technology has been demonstrated for S. aureus, E. coli, and Klebsiella pneumoniae (Lemmen et al 2003; Dan et al 2004). Also, bactericidal activity using synovial fluid bactericidal titer technology has been demonstrated for S. aureus, S. pyogenes, and K. pneumoniae (Dan et al 2004). Activity against S. pyogenes is independent of the presence/absence of macrolide resistance determinants (Critchley et al 2002).

Two recent studies have evaluated the activity of moxifloxacin in in vitro pharmacokinetic/pharmacodynamic models (IVP/PM) of mixed aerobic-anaerobic infection. Hermens and colleagues (2005) demonstrated bactericidal activity against Escherichia coli and Bacteroides fragilis in a study using a limited number of isolates of both microorganisms. Using different strains of the same microorganisms, Schaumann and colleagues (2005) demonstrated that the presence of B. fragilis did not affect the activity of moxifloxacin against E. coli but the presence of E. coli reduced the activity against B. fragilis significantly.

Another recent study evaluated the pharmacodynamics of moxifloxacin against anaerobes in an IVP/PM. B. fragilis, Clostridium perfringens, and Gram-positive anaerobic cocci (GPAC) were studied. Dose-ranging using area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC) ratios of 6.7 to 890 (for the reference aerobe E. coli) and 9 to 216 (for the anaerobe) revealed differing AUC/MIC antibacterial effect patterns for anaerobes versus the aerobe. For E. coli, the AUC/MIC ratios for 50%/90% effect were 34/59 while the corresponding values for B. fragilis, C. perfringens, and GPAC were 11/26, 9/16, and 7/17, respectively. At similar AUC/MIC ratio values, the activity against anaerobes was less than that against the aerobe. Using Monte Carlo simulations of human pharmacokinetic data and a target anaerobic AUC/MIC ratio value of 7.5, over 90% achievement of this target was possible at MICs < 2 mg/L. The clinical implications of this “pharmacokinetic breakpoint” of 2 mg/L for anaerobes deserves further study (Noel et al 2005).

Despite 10- to 20-fold accumulation of drug intracellularly (vida infra), the bactericidal effect of moxifloxacin intracellularly develops slowly, with only a 1.51 log reduction in post-phagocytosis S. aureus inoculum within 24 h (Seral et al 2003). This may be explainable, in part, by the deleterious effect of acid pH on activity. For example, at pH 5 (mimicking phagolysosome pH), moxifloxacin activity falls at least 4-fold compared with physiologic pH (Seral et al 2003). However, over a pH range of 6 to 8, moxifloxacin activity is unaffected for S. aureus and S. pyogenes (Dalhoff et al 2005).

The presence of 10%, 30%, and 50% albumin and human serum had no significant effect on the in vitro activity of moxifloxacin (Woodcock et al 1997; Rubinstein et al 2000). The presence of dead bacteria, sterile pus under aerobic conditions, sterile pus under anaerobic conditions, and anaerobic conditions alone had no significant effect on the in vitro activity of moxifloxacin against methicillin-sensitive and -resistant staphylococci, S. pyogenes, and E. coli (Boswell et al 1997; Rubinstein et al 2000; Wright et al 2002; Noel et al 2005). Anaerobic conditions also do not alter the AUC/MIC ratios for 50% and 90% of effect for E. coli and moxifloxacin (Noel et al 2005). Mixed effects have been noted when testing for an inoculum effect (Boswell et al 1997; Woodcock et al 1997).

Moxifloxacin has been evaluated in two mouse models relevant to skin and skin structure infections (systemic infection induced by intraperitoneal inoculation and cellulitis induced by subcutaneous (SC) inoculation). In the systemic infection model using 2 strains of methicillin-sensitive S. aureus (both having a moxifloxacin MIC of 0.06 mg/L), the ED50 and ED90 values for SC dosed drug were 0.6 mg/kg, 1.0 mg/kg and 1.7 mg/kg, 2.3 mg/kg, respectively, while corresponding ED values for orally dosed drug were 3.2 mg/kg (for both) and 9.6 mg/kg (for both) (Patel et al 2004). The term ED20/90 refers to the doses effective in producing survival rates of 50% and 90%, respectively. In the mouse cellulitis model, one methicillin-sensitive strain (MIC 0.03 mg/L) and two methicillin-resistant strains (MICs 1 mg/L and 4 mg/L) of S. aureus were used. For the methicillin-sensitive strain, 2.5 mg/kg and 5 mg/kg SC doses of moxifloxacin were administered 1 h, 4 h, 24 h, and 27 h post-inoculation while for the methicillin-resistant strains, 25 mg/kg and 50 mg/kg SC doses were administered 1 h, 3 h, and 5 h post-inoculation. With the methicillin-sensitive strain, moxifloxacin proved to be bacteriostatic (even 5 mg/kg doses led to a <2 log colony forming unit (CFU) reduction/lesion). With one methicillin-resistant strain, there was a marginal fall in CFU/lesion while with the other, it had no effect (CFU increased) (Patel et al 2004).

Two recent studies have evaluated the activity of moxifloxacin in animal models of osteomyelitis (bone infection). Bone infection can occur as a result of hematogenous seeding or contiguous spread from an area
of soft tissue infection. One study compared moxifloxacin and vancomycin in the treatment of bone infections due to methicillin-sensitive *S. aureus* in rats. Moxifloxacin (10 mg/kg) and vancomycin (15 mg/kg) were both dosed twice daily by the intraperitoneal route. Moxifloxacin was significantly more effective in reducing bacterial colony counts in femoral bone than were placebo and vancomycin (both p<0.001; placebo vs vancomycin, p=0.53). However, no treatment sterilized the infected bone, probably due to the presence of foreign material (i.e., the hollow needle maintained in the cavity) (Kalteis et al 2006a). The second study extended the findings of the first to include bacterial counts in infected capsular soft tissue and biofilm adherent to the implanted needle. Moxifloxacin was significantly superior to vancomycin and placebo in reducing bacterial counts in capsular soft tissue (both p<0.001; placebo vs vancomycin, p=0.09) and biofilm (p=0.009 and p<0.001, respectively; placebo vs vancomycin, p=0.20) (Kalteis et al 2006b). Further investigation of moxifloxacin in osteomyelitis appears warranted.

Another atypical mycobacterial infection with dermatological manifestations is leprosy (due to *M. leprae*). The classic test for evaluating the activity of antimicrobials against this microorganism is the mouse footpad model wherein the microorganism is injected into the footpad. In this model, where all drugs were administered orally, moxifloxacin proved superior to the quinolone used most frequently to date in combination regimens for leprosy, ofloxacin (percentages killed of 92.1% vs 60.2%, respectively; p<0.05). In addition, the combination of minocycline plus moxifloxacin was superior to that of minocycline plus ofloxacin (percentages killed of 93.7% vs 74.9%, respectively; p<0.05). Moxifloxacin was equipotent with rifampin, one of the key anti-leprosy drugs (percentage killed by both drugs was 92.1%, p=NS). The most potent combination tested was rifapentine (a rifamycin) plus minocycline plus moxifloxacin which produced a 99.9% killing rate (Ji and Grosset 2000). Moxifloxacin is an important agent to evaluate in vivo in human leprosy.

Performing large-scale surveillance of antimicrobial susceptibility can assist in deciding upon the selection of empiric antimicrobial therapy. In one such study, performed between 1994 and 2001, 12 US hospitals collected 4434 *Bacteroides* isolates for susceptibility testing. The overall moxifloxacin resistance rate rose from 30% to 43% (p<0.001) from 1998 to 2001 (2001 MIC<sub>90</sub> = 16 mg/L). Increased moxifloxacin resistance over time was noted in all species, all infection sites, and in 11 of 12 hospitals. For blood isolates, the resistance rate rose from 38% in 1998 to 52% in 2001. Resistance rates were especially high in the species *ovatus, uniformis*, and *vulgatus*. The largest increase in resistance occurred with the species *distasonis* (22% in 1999 to 37% in 2001). Of all infection sites, decubitus ulcer isolates had the highest resistance rates. On multivariate analysis, the association between the year of microorganism isolation and increased resistance rates remained significant after adjusting for hospital, species, and infection site (adjusted odds ratio=1.33, p<0.001) (Golan et al 2003).

In the LIBRA surveillance study in the US in 1999, 324 laboratories participated in an examination of resistance rates in *S. pyogenes* isolates. Isolates came from the respiratory tract (n=2039), skin and skin structure (n=405) and blood (n=148). The modal moxifloxacin MIC was 0.12 mg/L and the MIC<sub>90</sub> was 0.25 mg/L. One hundred percent of isolates were susceptible (based on a resistance breakpoint of ≥4 mg/L) (Critchley et al 2002).

In 2003, 37 laboratories in 19 countries participated in a survey of resistance rates among *B. fragilis* group isolates. Among the 1284 isolates (the majority coming from abdominal infections and wounds), 9% were resistant to moxifloxacin (breakpoint = 8 mg/L) (range 0%–22%). Moxifloxacin resistance was commonest in Mediterranean Europe (15%) and the UK (22%). In the various infection types, the rates of intermediate (decreased susceptibility) plus resistant isolates were as follows: abdominal infections (5%), wounds (13%), abscesses (4%), blood (11%), and external ulcers/skin infections (16%) (Hedberg et al 2003).

In 2005, results of a six-year (1997-2002) surveillance study of moxifloxacin susceptibility among *B. fragilis* group organisms at a single hospital in Spain were published. Resistance rates to moxifloxacin rose from 6% (1997) to 16.5% (2002), using an MIC breakpoint of 8 mg/L (p=0.005 for trend). Examining resistance rates by species, these rates rose over six years from 1.5% to 12% (*B. fragilis*), 10.3% to 25% (*B. thetaiotaomicron*), and 15.4% to 36.8% (*B. uniformis*) (Betriu et al 2005).

Results of the SENTRY Antimicrobial Surveillance Program (1997–2004) have revealed the emergence in North America and Europe of quinolone resistance among β-hemolytic streptococci (groups A, B, C, G). Although rates are low at present (0.51% and 0.14% in North America and Europe, respectively), further dissemination and expansion of resistance determinants is likely (Biedenbach et al 2006).
Pharmacokinetics

Moxifloxacin is well-absorbed after oral administration, with absolute oral bioavailabilities of 92% (mean) (range 77%–120%) and 86.2 ± 1.11% (mean ± standard deviation [SD]) being noted in 2 healthy-volunteer studies (Ballow et al 1999; Stass and Kubitz 1999). Oral administration in the fed state (high fat breakfast) had nonsignificant effects on moxifloxacin peak plasma concentration (C_max) and area under the plasma concentration-versus-time curve (AUC) but did prolong the median time to C_max (T_max) from 1 to 2.5 hours (not clinically significant) (Lettieri et al 2001). Milk (240–300 mL) and yogurt (250–300 mL) coadministration did not significantly alter moxifloxacin bioavailability (Guay 2005) nor did enteral feeding coadministration (Burkhardt et al 2005). Minor accumulation occurs during multiple dosing and its pharmacokinetics are linear and dose-proportional (Stass et al 1998, 2001; Sullivan et al 1999).

Mean ± SD plasma protein binding values of moxifloxacin were 48% ± 2.5% (Stass et al 1998) and 39.4% ± 2.4% (Stass and Kubitz 1999). Plasma protein binding of the M1 sulfocompound metabolite was 89.5% ± 0.9% and that of the M2 glucuronide metabolite was 4.8% ± 4.1% (Stass and Kubitz 1999). Penetration of moxifloxacin into body compartments relevant to skin and skin structure infections has been the subject of several studies. In one healthy volunteer study, the pharmacokinetics of moxifloxacin in plasma and inflammatory blister fluid (induced by cantharides plasters) were evaluated after single 400 mg oral and intravenous doses. The mean ± SD (range) penetration of moxifloxacin into inflammatory blister fluid after oral and intravenous dosing was 83.5% ± 14.9% (61%–103%) and 93.7% ± 8.3% (81%–104%), respectively, as measured by AUC_{BF}/AUC_{total plasma} (Muller et al 1999). In another study, the serum and synovial fluid concentrations of moxifloxacin after the last of three once-daily oral moxifloxacin 400 mg doses were assessed in 20 patients undergoing knee arthroscopy (mean age of 71.2 years). At 2 h, 6 h, 12 h, and 24 h after the last dose, the mean ± SD serum/synovial fluid concentrations were 2.42 ± 0.4/2.76 ± 0.24 mg/L, 3.46 ± 0.78/3.42 ± 0.51 mg/L, 1.74 ± 0.26/1.61 ± 0.5 mg/L, and 1.5 ± 0.21/1.23 ± 0.14 mg/L, respectively (Dan et al 2004).

In yet another healthy volunteer study, the penetration of moxifloxacin into the interstitial fluid compartments of muscle and SC adipose fat tissue and inflammatory blister fluid were evaluated after single 400 mg oral and intravenous doses. Mean ± SD penetration into muscle interstitial fluid was 55% ± 12% (using AUC_{muscle}/AUC_{total plasma} data) and 86% ± 17% (using AUC_{muscle}/AUC_{free plasma} data). Corresponding SC adipose fat interstitial fluid penetration was 38% ± 9% and 81% ± 19%. These results suggest a virtually total equilibration between these two body compartments and free (unbound) drug in plasma. The concentration over time profiles in these two compartments were virtually superimposable. Mean ± SD penetration into inflammatory blister fluid (BF) was 64% ± 21% (using AUC_{BF}/AUC_{total plasma} data) (Muller et al 1999).

The penetration of moxifloxacin into healthy and inflamed SC adipose fat tissues was assessed in 11 patients with skin and skin structure infections (n=5 had diabetes and peripheral occlusive arterial disease [POAD], n=6 did not). A single 400 mg IV dose of moxifloxacin was administered over one hour. In the aggregate analysis (n=11), drug concentrations in healthy and inflamed tissues were consistently below total plasma concentrations and approximately equal to free plasma concentrations. Moxifloxacin total plasma concentration over time profiles were similar in patients with and without diabetes/POAD. Penetration into tissue did not statistically differ in the two groups. In patients with diabetes/POAD, the concentrations in healthy tissue exceeded those in inflamed tissue. Only the healthy tissue concentrations were similar to the free concentrations in plasma (the inflamed tissue concentrations were about 1/2 of the free concentrations in plasma). In the patients without diabetes, exactly the opposite findings were noted. Thus, the mean ± SD AUC_{0-8h} for inflamed tissue/ AUC_{0-8h} for free drug in plasma was 0.5 ± 0.4 in patients with diabetes/POAD and 1.2 ± 0.8 in the other group. Mean ± SD inflamed tissue C_max values were 0.8 ± 0.5 mg/L in patients with diabetes/POAD and 2.3 ± 1.2 mg/L in the other group. The reduced concentrations in inflamed tissues in patients with versus without diabetes/POAD was perhaps due to the vascular compromise associated with POAD. None of these differences between patients with/without diabetes/POAD were significant due to small sample sizes and large interpatient variability. In all cases, tissue and plasma drug concentrations exceeded the MICs of most dermatologic pathogens, suggesting a role for moxifloxacin in the treatment of skin and skin structure infections (Joukhadar et al 2003).

Thirty patients undergoing total knee arthroplasty participated in a study investigating the penetration of moxifloxacin into bone. Ten patients received oral moxifloxacin 2 h (range 1.5–2.5 h) preoperatively and mean plasma, cancellous bone, and cortical bone drug concentrations were 3.45 mg/L, 1.89 mg/kg, and 1.43 mg/
kg, respectively. In the ten patients receiving moxifloxacin 4 h (range 3.5–4.5 h) preoperatively, corresponding mean drug concentrations were 3.73 mg/L, 1.81 mg/kg, and 1.56 mg/kg. In the ten patients receiving the drug 14 h and 2 h (range 1.5–2.5 h) preoperatively, corresponding drug concentrations were 6.26 mg/L, 2.97 mg/kg, and 2.54 mg/kg (Malincarne et al 2006).

As with other quinolones, moxifloxacin penetrates well into polymorphonuclear leukocytes (mean ± SD internal concentration = 54 ± 0.5 mg/L with an external medium concentration of 4.5 mg/L) (Mandell and Coleman 2001). Moxifloxacin also penetrates well into macrophages (with an external concentration of 4 mg/L, the mean internal–external concentration ratio = 13.4 (in cells infected with S. aureus) and 11.4 (in non-infected cells), p=0.02) (Seral et al 2003).

Moxifloxacin elimination occurs via a combination of hepatic metabolism, biliary secretion, renal excretion, and, perhaps, transintestinal secretion. It is metabolized to 2 inactive metabolites, M1 (N-sulfate) and M2 (acylglucuronide) (Stass et al 2004). Renal clearance (CLR) for the parent compound involves glomerular filtration and inactive metabolites, M1 (N-sulfate) and M2 (acylglucuronide) (Stass et al 2004). Renal clearance (CLR) for the parent compound involves glomerular filtration and partial renal tubular reabsorption (Stass et al 1998; Stass and Kubitza 1999). Fecal drug concentrations upon multiple oral dosing are quite high, a result of nonabsorption, biliary secretion, and, possibly, transintestinal secretion (mean ± SD days 2, 4, and 7 values during 400 mg daily oral dosing were 87.3 ± 2.4 mcg/g, 303.3 ± 1.8 mcg/g, and 573.3 ± 1.9 mcg/g, respectively) (Burkhardt et al 2002). Mass balance studies using oral drug have demonstrated that (mean ± SD) 44.8% ± 3.4%, 37.9% ± 3.6%, and 13.6% ± 2.8% of the dose is eliminated as moxifloxacin (19.4% ± 1.2% in urine and 25.4% ± 3.1% in feces), M1 metabolite (2.5% ± 0.6% in urine and 35.5% ± 3.2% in feces) and M2 metabolite (13.6% ± 2.8% in urine and none in feces), respectively (Stass and Kubitza 1999). Thus, the urinary and fecal routes account for 35.4% ± 1.8% and 60.9% ± 5.1% of the dose, respectively (Stass and Kubitza 1999). The M1 metabolite is a high clearance compound eliminated mainly via hepatic metabolism and biliary secretion into the feces. Renal secretion occurs via a net active tubular secretion process (Stass and Kubitza 1999). The M2 metabolite is the main metabolite seen in plasma, undergoing some presystemic clearance via glucuronidation and excretion by the kidneys by active tubular secretion. Biliary/fecal elimination is negligible (Stass and Kubitza 1999). A summary of the pharmacokinetic parameters for moxifloxacin in healthy volunteers is provided in Table 3 (Stass et al 1998, 2001, 2002, 2004; Ballow et al 1999; Stass and Kubitza 1999; Sullivan et al 1999, 2001; Wise et al 1999; Lubasch et al 2000; Lettieri et al 2001; Burkhardt et al 2002).

When pharmacokinetic parameters are weight-normalized, there are no significant age- or gender-based effects on moxifloxacin pharmacokinetics (Sullivan et al 2001; Pea et al 2006). Thirty-two individuals participated in a single 400 mg oral dose study of the effects of renal impairment on the pharmacokinetics of moxifloxacin and its M1 and M2 metabolites. With moxifloxacin, there was no significant relationship of AUC with creatinine clearance (CrCl) (p=0.59). However, Cmax did fall as CrCl fell (p=0.03). Significant correlations existed between moxifloxacin Cmax (r=0.438, p=0.012), fractional renal excretion (F e) (r=0.613, p=0.0002) and CLR (r=0.6405, p=0.0001) and CrCl. The M1 metabolite was little affected by changes in renal function although significant correlations existed between M1 metabolite F e (r=0.620, p=0.0002) and CLR (r=0.703, p<0.0001) and CrCl. CLR (r=0.736, p<0.0001) and CrCl rose as CrCl fell (p=0.0167) while Cmax did not change (p=0.3042). Significant correlations existed between M2 metabolite AUC (r=0.565, p=0.0011), CLR (r=0.736, p<0.0001) and F e (r=0.514, p=0.0026) and CrCl (Stass et al 2002).

Single and multiple dose pharmacokinetics of moxifloxacin in skin infections have also been evaluated in end-stage renal disease patients undergoing hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD). Following a single oral 400 mg dose, the AUC’s of parent compound in these patients were statistically similar to those found generally in healthy volunteers. However, Cmax values were reduced by about 45% (HD) and 33% (CAPD) compared with historical healthy control subject data. The systemic exposure to the M1 metabolite rose by 1.4- to 1.5-fold (based on AUC) while that to the M2 metabolite rose 7.5-fold (based on AUC) and 2.5- to 3-fold (based on on Cmax) compared with historical healthy control subject data. The possible consequences of increased metabolite exposure are not known. Multiple once-daily oral dosing of 400 mg for 7 days in these patients produced systemic exposure (AUC) similar to that seen in healthy volunteers. Steady-state Cmax values in HD patients were approximately 22% lower than those in healthy volunteers while they were comparable for CAPD patients. Dialysis removal of moxifloxacin was low (9% by HD, 3% by CAPD) (Anonymous 2005). Continuous renal replacement therapy (continuous venovenous hemodiafiltration) does not affect
## Table 3
Mean ± SD pharmacokinetic parameters of moxifloxacin in healthy adult volunteers

| Reference | n     | Regimen                  | \( C_{\text{max}} \) (mg/L) | \( T_{\text{max}} \) (h) | \( t_{1/2} \) (h) | \( \text{CL/F} \) (L/h) | \( \text{CL}_R \) (L/h) | \( F_e \) (%) |
|-----------|-------|--------------------------|-----------------------------|---------------------------|-----------------|------------------------|------------------------|--------------|
| (1)       | 11    | 400 mg PO x 1            | 2.53 ± 1.31                 | 1.0*                      | 14.6 ± 1.18     | 13.7 ± 1.16            | 3.17 ± 1.12            | 23.2 ± 2.7    |
| (2)       | 12    | 400 mg PO qd             |                            |                           |                 |                        |                        |              |
|           | dose 1| 3.10 ± 0.60\( ^b \)       | 1.67 ± 0.96                 | 10.6\( ^b \)             | 11.6 ± 2.1      |                        |                        |              |
|           | dose 7| 3.98 ± 1.10\( ^b \)       | 1.59 ± 0.79                 | 14.9\( ^b \)             | 10.4 ± 2.0      |                        |                        |              |
| (3)       | 12    | 400 mg PO x 1            | 2.50 ± 1.29                 | 2.0\( ^a \)              | 15.6 ± 1.15     | 11.6 ± 1.21            | 2.58 ± 1.25            | 19.3 ± 2.8    |
| (4)       | 8     | 400 mg PO x 1            | 4.38 ± 1.4                  | 0.77\( ^a \)             | 14.9 ± 1.5      | 9.2 ± 1.4              | 2.3 ± 1.3              | 24.2 ± 1.4    |
| (5)       | 16    | 400 mg PO x 1            | 2.8 (31.7%)\( ^c \)        | 1.0\( ^a \)              | 11.5 (12.8%)\( ^c \) |                        |                        |              |
| (6)       | 8\( ^d \)| 200 mg PO x 1        | 1.31                        | 1.28                      | 13.16           | 10.61                  | 2.25                  | 19.63         |
|           | 8\( ^e \)|                        |                            |                           |                 |                        |                        |              |
|           | 8\( ^f \)|                        |                            |                           |                 |                        |                        |              |
| (7)       | 8     | 100 mg PO bid x 5 days   |                            |                           |                 |                        |                        |              |
|           | day 1 | 0.63 ± 1.47              | 2.0\( ^a \)                | 9.39 ± 1.08              | 13.1 ± 1.25     | 2.54 ± 1.28            | 15.8 ± 1.21            |              |
|           | day 5 | 0.90 ± 1.28              | 1.5\( ^a \)                | 13.7 ± 1.20              | 13.8 ± 1.22     | 3.32 ± 1.31            | 24.0 ± 1.24            |              |
| (8)       | 12    | 400 mg PO x 1            | 4.34 ± 1.61                 | 1.02 ± 0.72              | 9.15 ± 1.62     |                        |                       | 30.5 ± 6.10\( ^f \) | 19.9 ± 4.55  |
| (9)       | 7     | 400 mg PO x 1            | 4.98 ± 1.01                 | 1.0 ± 0.91               | 8.32 ± 1.70     | 147.8\( ^b \)         | 22.3\( ^b \)          | 15.10 ± 3.61  |
|           | 400 mg IV x 1 |                        | 5.09 ± 1.11               |                        | 8.17 ± 1.58     | 151.5\( ^b \)         | 23.0\( ^b \)          | 15.2 ± 3.40  |
| (10)      | 10    | 100 mg PO x 1            | 1.15                        | 0.86                     | 13.5            |                        |                       | 24.4         |
|           | 100 mg IV x 1 |                        | 1.34                        |                        | 12.7            |                        |                       | 25.3         |
| (11)      | 7\( ^i \)| 400 mg PO qd x 10 days | 3.36 (21.5%)\( ^c \)       | 1.49 (62.2%)\( ^c \)     | 9.30 (12.1%)\( ^c \) |                        |                        |              |
|           | day 10 | 4.52 (12.2%)\( ^c \)    | 1.24 (48.0%)\( ^c \)       | 11.95 (10.8%)\( ^c \)   |                        |                        |                        |              |
|           | 400 mg PO x 1 |                        | 2.53 ± 1.31               | 1.0\( ^a \)             | 14.6 ± 1.18     | 13.7 ± 1.16            | 3.17 ± 1.12            | 23.2 ± 2.7    |
| (12)      | 6     | 50 mg PO x 1             | 0.29 ± 1.25                 | 1.75\( ^a \)             | 11.4 ± 1.11     | 12.9 ± 1.13            | 2.77 ± 1.22            | 20.4 ± 1.15   |
|           | 100 mg PO x 1 |                        | 0.59 ± 1.21               | 2.0\( ^a \)             | 12.2 ± 1.11     | 11.8 ± 1.21            | 2.38 ± 1.25            | 18.9 ± 1.34   |
|           | 6      | 200 mg PO x 1            | 1.16 ± 1.35                 | 2.50\( ^a \)             | 14.0 ± 1.14     | 13.0 ± 1.20            | 2.64 ± 1.25            | 19.8 ± 1.16   |
|           | 7      | 400 mg PO x 1            | 2.50 ± 1.31                 | 1.5\( ^a \)             | 13.1 ± 1.06     | 14.9 ± 1.18            | 3.03 ± 1.17            | 20.1 ± 1.20   |
|           | 6      | 600 mg PO x 1            | 3.19 ± 1.19                 | 2.5\( ^a \)             | 12.5 ± 1.14     | 15.0 ± 1.11            | 2.67 ± 1.10            | 17.5 ± 1.16   |
|           | 7      | 800 mg PO x 1            | 4.73 ± 1.63                 | 3.0\( ^a \)             | 12.3 ± 1.13     | 13.4 ± 1.24            | 2.50 ± 1.28            | 18.7 ± 1.25   |

**Abbreviations:** bid, twice daily; \( C_{\text{max}} \), peak serum concentration; \( \text{CL/F} \), total body clearance; \( \text{CL}_R \), renal clearance; \( F_e \), fractional elimination in urine as unchanged parent compound; IV, intravenous; \( T_{\text{max}} \), time to peak; \( t_{1/2} \), terminal disposition half-life; PO, oral; qd, once daily.

**Notes:**
- *Median;
- *Links parameters that are significantly different (\( p \leq 0.05 \));
- % coefficient of variation;
- *Young males (mean age, 32);
- *Older males (mean age, 74);
- *Older females (mean age, 74);
- *Mean values in mL/min; Male; Female.

**References:**
1, Stass et al 2004; 2, Burkhardt et al 2002; 3, Stass and Kubista 1999; 4, Stass et al 2002; 5, Lettieri et al 2001; 6, Sullivan et al 2001; 7, Stass et al 2001; 8, Lubasch et al 2000; 9, Wise et al 1999; 10, Ballow et al 1999; 11, Sullivan et al 1999; 12, Stass et al 1998.
moxifloxacin disposition to a clinically-meaningful extent (Fuhrmann et al 2004).

Clinical efficacy

This section will deal only with the clinical efficacy of moxifloxacin in skin and skin structure infections (SSSIs). Table 4 illustrates the results of moxifloxacin clinical trials in uncomplicated and complicated SSSIs (Leal del Rosal, Fabian, et al 1999; Leal del Rosal, Martinez, et al 1999; Parish et al 2000; Anonymous 2005; Giordano et al 2005). All have been active-controlled in design, with cephalexin as the control in the three uncomplicated SSSI studies, unspecified β-lactam/β-lactamase-inhibitor combinations in the 2 unpublished complicated SSSI studies, and piperacillin-tazobactam followed by amoxicillin-clavulanate as the control in the one published complicated SSSI study. As may be seen, there were no significant or substantial inter-group differences in clinical or bacteriological efficacy or tolerability.

These results should be interpreted while keeping in mind potential study limitations. In general, these studies did not provide evidence of power analyses conducted to establish proper group sizes. Thus, they were underpowered to avoid type II statistical errors (ie, false negative intergroup differences), especially with respect to subgroup analyses based on comorbidities or individual pathogens. Three of five studies remain unpublished, available only as abstracts or in the product information. The limitations of this should be obvious to the reader. The extensive number and breadth of exclusion criteria generated study populations much different from the “real world” patients who would require treatment. Hence, the generalizability of study results can be questioned. Clinical trials of SSSIs have long been difficult to design in a way that renders them rigorous and reproducible. Although the publication of SSSI study design criteria by the Infectious Diseases Society of America (IDSA) have helped in this regard (Calandra et al 1992), deficient study designs are, unfortunately, still far too frequently seen. The ability of investigators to add anaerobic coverage (eg, metronidazole) for presumed mixed SSSIs makes it impossible to judge whether or not the anaerobic coverage of moxifloxacin is clinically-relevant. Lastly, the definitions of clinical endpoints can vary between SSSI studies, making it difficult to obtain a global perspective of drug efficacy.

A recent case report detailed a case of a patient with an infected cat-bite wound failing therapy with IV cefuroxime, ciprofloxacin, and metronidazole which responded to the addition of IV moxifloxacin (Draenert et al 2005). Another case report documented successful therapy of a M. thermoresistibile infection following knee replacement surgery with long-term therapy using moxifloxacin and doxycycline (Labombardi et al 2005).

A recent review of potential antitubercular drugs included encouraging in vitro, in vivo, and pilot human clinical data regarding moxifloxacin use in infections due to M. tuberculosis (Duncan and Barry 2004). These data, in conjunction with in vitro susceptibility data reviewed earlier in this paper, suggest that moxifloxacin may play an important role in the treatment of SSSIs caused by atypical mycobacteria. Clinical trials in this area are warranted.

Safety

As with other quinolones, moxifloxacin is generally well-tolerated, with the majority of adverse events referable to the gastrointestinal tract (nausea, diarrhea, vomiting, constipation, abdominal pain, vaginitis, taste alteration) or the central nervous system (headache, dizziness) (Anonymous 2005). There were only three adverse events, judged by investigators to be at least possibly drug-related, occurring in at least 2% of over 8600 moxifloxacin-treated patients in the drug development process: nausea (6%), diarrhea (5%), and dizziness (2%) (Anonymous 2005). Premature study discontinuation rates for drug-related adverse events were 2.9% (oral) and 4.6% (IV → oral) (Anonymous 2005). Moxifloxacin is not associated with the phototoxicity characteristic of lomefloxacin and sparfloxacin (Man et al 1999) and has only been associated with the “temafloxacin hypersensitivity syndrome” in 1 patient (Nori et al 2004). This patient exhibited toxic epidermal necrolysis and fulminant hepatic failure leading to death. Moxifloxacin is not associated with the hypo or hyperglycemia seen with gatifloxacin therapy (Park-Wyllie et al 2006).

In 2004, a cumulative safety review of oral and intravenous moxifloxacin from the drug development program and postmarketing surveillance studies was published. For the oral agent, the database comprised 30 phase II/III active comparator studies (moxifloxacin n=7368, comparators n=5687), one phase IV study (n=18374), and 4 postmarketing observation studies (n=27756). For the intravenous agent, the database comprised two phase III active comparator studies (moxifloxacin n=550, comparators n=579). With both formulations, the commonest adverse events involved the gastrointestinal tract (for the oral agent, nausea in 7.1% and
| Reference Design | # evaluable subjects (C/B)* | Regimens | Results |
|------------------|-----------------------------|----------|---------|
| Uncomplicated SSSIs (1) | MC/R/DB/PG 180/68 | Moxi 400 mg PO qd x 7 days | Clinical cure/improvement rates at 7–21d after the end of therapy were 90% (Moxi) and 91% (Ceph) (p=NS). Clinical response rates were lower in men than women, esp. with Moxi (86% men, 94% women; stats NA). Clinical response rates were highest in ≥65 yo age group (95%, stats NA). Clinical response rates with Ceph were approx. equivalent for spontaneous infections and those occurring with a wound while, for Moxi, rates were higher for infections occurring with a wound (96% vs. 87%, stats NA). Bact. eradication/presumed eradication rates at 7–21 days after the end of therapy were 91% in both groups (stats NA). For S. aureus, eradication rates were 92% (Moxi) and 93% (Ceph) (stats NA) while for Streptococcus species they were 90% (Moxi) and 82% (Ceph) (stats NA). AE profiles for the 2 drugs were similar (stats NA). AEs occurred in 21% of Moxi and 19% of Ceph patients. 9 AEs were serious/life-threatening in 7 patients (1 with Moxi, 6 with Ceph). AEs led to premature study D/C in 13 patients (6 Moxi, 7 Ceph). Majority of AEs were referable to GI tract and skin and frequencies/types were similar in the 2 groups. |
| MC/R/DB/PG 171/57 | Ceph 500 mg PO tid x 7 days | | |
| MC/R/DB/PG 191/100 | Moxi 400 mg PO qd x 5–14 days | 91/100 | Clin. cure or improvement occurred in 93% of patients in both groups. Bact. eradication/presumed eradication occurred in 89% (Moxi) and 94% (Ceph) of patients. Eradication rates for S. aureus were 92% (Moxi) and 89% (Ceph). No mention was made of AEs and results of statistical analyses NA. |
| MC/R/DB/PG 194/112 | Ceph 500 mg PO tid x 5–14 daysb | |
| MC/R/DB/PG 21/18 | Moxi 200 mg PO qd x 5–14 days | 21/18 | Clin. cure or improvement occurred in 95% (Moxi 200), 100% (Moxi 400), and 89% (Ceph) of patients. Corresponding bact. eradication/presumed eradication rates were 72%, 80%, and 80%. Predominant pathogens were S. aureus (37.5%), S. haemolyticus (18.8%), and E. faecalis (10.4%). All treatments were “well-tolerated” with “similar frequencies of drug-related AEs”. Results of statistical analyses NA. |
| MC/R/DB/PG 22/15 | Moxi 400 mg PO qd x 5–14 days | |
| 26/15 | Ceph 500 mg PO tid x 5–14 days | |
| Complicated SSSIs (4) | MC/R/DB/PG (North America) 162/NA | Moxi IV → PO (total of 7–14 days) | Clin. cure or improvement occurred in 77.2% of Moxi and 81.5% of β-lactam comparator recipients (p=NS). |
| MC/R/DB/PG 173/NA | β-lactam/β-lactamase inhibitor IV → PO (total of 7–14 days) | |

**Note:** aClinically/bacteriologically; bCould add metronidazole 400 mg tid for anaerobic coverage; cMethicillin-susceptible strains.

**Abbreviations:** AE, adverse event; Amox-Clav, amoxicillin-clavulanate; Ceph, cephalexin; CHF, chronic heart failure; DB, double-blind; D/C, discontinuation; GI, gastrointestinal; IV, intravenous; I + D, incision + drainage; MC, multicenter; Moxi, moxifloxacin; NA, not available; NS, non-significant; PG, parallel group; R, randomized; qd, once daily; tid, thrice daily; Pip-Tazo, piperacillin-tazobactam; PMC, pseudomembrous colitis; PO, oral.

**Reference key:** 1, Parish et al 2000; 2, Leal del Rosal, Fabian, et al 1999; 3, Leal del Rosal, Martinez, et al 1999; 4, Anonymous 2005; 5, Giordano et al 2005.
### Table 4 Continued

| Reference Design | Regimens | Results |
|------------------|----------|---------|
| MC/R/PG (International) | Moxi 400 mg IV → PO qd x 7–21 days | Clin. cure or improvement occurred in 80.6% of Moxi and 84.5% of β-lactam comparator recipients (p=NS). |
| 315/NA | Moxi 400 mg IV → PO qd x 7–21 days | Pooled results (stats NA) Surgical I + D or debridement occurred in 55% of Moxi and 53% of β-lactam comparator subjects. Success rates varied by diagnosis (61% in infected skin ulcers to 90% in complicated erysipelas). Clin. cure or improvement by pathogen was as follows: S. aureus: Moxi 82.2%, Comparator 87.6% E. coli: Moxi 81.6%, Comparator 84.8% K. pneumoniae: Moxi 91.7%, Comparator 70.0% E. cloacae: Moxi 81.8%, Comparator 57.1% |
| 317/NA | β-lactam/β-lactamase inhibitor IV → PO (total of 7–21 days) | Surgical I + D or debridement occurred in 55% of Moxi and 53% of β-lactam comparator subjects. Success rates varied by diagnosis (61% in infected skin ulcers to 90% in complicated erysipelas). Clin. cure or improvement by pathogen was as follows: S. aureus: Moxi 82.2%, Comparator 87.6% E. coli: Moxi 81.6%, Comparator 84.8% K. pneumoniae: Moxi 91.7%, Comparator 70.0% E. cloacae: Moxi 81.8%, Comparator 57.1% |
| MC/R/DB/PG | Moxi 400mg IV → PO (total of 7–14 days) | Clin. cure rates 10–42 days post-therapy were 79% (Moxi) and 82% (Pip-Tazo → Amox-Clav) (p=NS). Clin. cure rates were similar by infection type in the 2 groups except abscess (79% Moxi vs. 93% Pip-Tazo → Amox-Clav, p=0.04). Univariate followed by multivariate regression analysis identified the no. of surgeries (ie, ≥2) as being an independent risk factor for failure of abscess cure. After adjusting for risk factors for failure of abscess cure, the difference between groups disappeared (odds ratio, 1.05; p=0.12). There were no significant differences between the groups in bacteriologic eradication rates by organism or for monomicrobial or polymicrobial infections. AE rates were comparable in the 2 groups (drug-related AEs in 31% and 30% of Moxi and Pip-Tazo → Amox-Clav patients, respectively; corresponding rates of diarrhea were 5% and 8%, and nausea were 4% and 2%; premature D/C for drug-related AEs in 14 and 17 patients). Drug-related serious AEs with Moxi included weakness, worsening of drug reaction rash, cellulitis exacerbation, PMC, and clinical failure and with Pip-Tazo → Amox-Clav included cardiopulmonary arrest, worsening CHF, allergic reaction, asthenia, worsened skin eruption, allergic reaction, persistent right leg abscess, bloody diarrhea, osteomyelitis, and clinical failure. |
| 180/119 | Pip-Tazo 3.375 g IV qd → Amox-Clav PO 800 mg bid (total of 7–14 days) | Clin. cure rates 10–42 days post-therapy were 79% (Moxi) and 82% (Pip-Tazo → Amox-Clav) (p=NS). Clin. cure rates were similar by infection type in the 2 groups except abscess (79% Moxi vs. 93% Pip-Tazo → Amox-Clav, p=0.04). Univariate followed by multivariate regression analysis identified the no. of surgeries (ie, ≥2) as being an independent risk factor for failure of abscess cure. After adjusting for risk factors for failure of abscess cure, the difference between groups disappeared (odds ratio, 1.05; p=0.12). There were no significant differences between the groups in bacteriologic eradication rates by organism or for monomicrobial or polymicrobial infections. AE rates were comparable in the 2 groups (drug-related AEs in 31% and 30% of Moxi and Pip-Tazo → Amox-Clav patients, respectively; corresponding rates of diarrhea were 5% and 8%, and nausea were 4% and 2%; premature D/C for drug-related AEs in 14 and 17 patients). Drug-related serious AEs with Moxi included weakness, worsening of drug reaction rash, cellulitis exacerbation, PMC, and clinical failure and with Pip-Tazo → Amox-Clav included cardiopulmonary arrest, worsening CHF, allergic reaction, asthenia, worsened skin eruption, allergic reaction, persistent right leg abscess, bloody diarrhea, osteomyelitis, and clinical failure. |

**Note:** aClinically/bacteriologically; bCould add metronidazole 400 mg tid for anaerobic coverage; cMethicillin-susceptible strains.

**Abbreviations:** AE, adverse event; Amox-Clav, amoxicillin-clavulanate; Ceph, cephalaxin; CHF, chronic heart failure; DB, double-blind; D/C, discontinuation; GI, gastrointestinal; IV, intravenous; I + D, incision + drainage; MC, multicenter; Moxi, moxifloxacin; NA, not available; NS, non-significant; PG, parallel group; R, randomized; qd, once daily; tid, thrice daily; Pip-Tazo, piperacillin-tazobactam; PMC, pseudomembranous colitis; PO, oral.

**Reference key:** 1, Parish et al 2000; 2, Leal del Rosal, Fabian, et al 1999; 3, Leal del Rosal, Martinez, et al 1999; 4, Anonymous 2005; 5, Giordano et al 2005.
diabetes in 5.2%; for the intravenous agent, nausea in 3.1% and diarrhea in 6.2%). Premature discontinuation rates due to adverse events to moxifloxacin were 2.7% (oral) and 6.0% (intravenous) while mortality rates were 2.7% (oral) and 4% (intravenous). Cardiovascular adverse events, including surrogate markers for arrhythmias such as tachycardia, palpitations, syncope, and hypotension, occurred at rates far below 1%. Blood sugar-related events were practically nonexistent (Ball et al 2004).

In the same year, a similar retrospective review of the phase II/III clinical trial database (32 trials, n=14731 patients (moxifloxacin n=8474, active comparators n=6257)) and postmarketing surveillance studies (n=46130) were reviewed with a focus on adverse events involving glucose metabolism. In the clinical trials, there were 0 and 3 drug-related hypoglycemic adverse events with moxifloxacin and active comparator patients, respectively (latter were 2 cases with levofloxacin and 1 case with trovafloxacin). Drug-related hypoglycemic events occurred in 7 moxifloxacin and 1 active comparator patients. No evidence was found supporting the presence of drug–drug interactions with oral antidiabetic drugs. In the postmarketing studies, no cases of drug-related hypoglycemia were noted. This same paper described results of in vivo (rat) studies utilizing single 30 mg/kg and 100 mg/kg oral doses of moxifloxacin, gatifloxacin, and levofloxacin (positive control was glibenclamide 10 mg/kg). Blood was sampled predosing and at 0.5 h and 1.5 h postdosing. In fasted rats, glibenclamide had the expected effect (blood glucose fell a mean of 24% at 1.5 h postdose which was preceded by a rise in serum insulin). Blood glucose was not significantly affected by either moxifloxacin or levofloxacin but fell means of 8% and 18% with 30 mg/kg and 100 mg/kg doses of gatifloxacin, respectively. No significant effects on serum insulin were noted with any quinolone. In fed rats, glibenclamide increased serum insulin and reduced blood glucose approximately 40% at 1.5 h postdosing. Again, moxifloxacin and levofloxacin had no significant effect on blood glucose or serum insulin. Gatifloxacin 30 mg/kg and 100 mg/kg reduced blood glucose by means of 17% and 26%, respectively. This was preceded by a reduction in serum insulin (only significant at 0.5 h with 100 mg/kg dose). Thus, the gatifloxacin effect was felt to be insulin-independent (Gavin et al 2004).

Results of the last of the large retrospective database reviews for safety purposes were published in 2005 and focused on the safety of oral moxifloxacin in the clinical trial database as a function of aging. The database involved 27 phase II/III clinical trials analyzed by age grouping (<65, 65–74, ≥75 years old) and treatment (moxifloxacin and active comparators). Valid data were available from 12231 subjects (moxifloxacin n=6270, active comparators n=5961; comparators were primarily clarithromycin and cefuroxime axetil). The subject distribution by age was as follows: n=9671 were <65, n=1631 were 65–74, and n=924 were ≥75 years old. The distribution of drug-related adverse events comparing moxifloxacin with active comparators was not affected by increasing age (p=0.43) nor were premature discontinuations due to adverse events (p=0.552). The number of deaths were also similar (moxifloxacin n=17, active comparator n=19). No arrhythmias due to QTc interval prolongation were noted in the entire population. The differences in adverse event profiles across the 3 age groups were not significant for moxifloxacin (p=0.599) with 1 exception. For drug-related adverse events with moxifloxacin, the profiles did differ across the 3 age groups (p=0.001) but, unexpectedly most rates increased as age fell (eg, nausea, vomiting, dyspepsia, and vaginal moniliasis rates rose as age fell but insomnia rates rose as age rose). There were no clinically-significant differences between the treatments in the prevalence of serious drug-related events (≤1%) and these were not related to age. In 787 patients who had pre and 3 day-post 12-lead electrocardiograms (n=651 were <65, n=136 were ≥65 years old), the mean ± SD QTc interval prolongation was 7 ± 25 msec in the <65 group and 2 ± 28 msec in the ≥65 group (p=0.055, trend) (Andriole et al 2005).

Pharmacokinetic drug–drug interactions

Based on the significant role of metabolism in the elimination of moxifloxacin, a study was conducted to evaluate the effect of concurrent use of a potent cytochrome P450 isozyme 3A4 inhibitor (itraconazole) on moxifloxacin pharmacokinetics. Nine days of itraconazole 200 mg orally daily had no significant effect on the single-dose kinetics of oral moxifloxacin 400 mg (administered on day 7 of the 9-day itraconazole regimen). Moxifloxacin also had no significant effect on itraconazole kinetics (Stass et al 2004). Moxifloxacin 400 mg orally daily had no significant effect on theophylline total body clearance and terminal disposition half-life in 2 studies (Guay 2005). Moxifloxacin 400 mg orally once daily had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin in healthy volunteers (Guay 2005). However, case reports have documented moxifloxacin-associated increases in INR.
Moxifloxacin in skin infections

(international normalized ratio of prothrombin time) in warfarin recipients (Elbe and Chang 2005; Guay 2005). Pending additional information, patients receiving long-term warfarin therapy in whom moxifloxacin is to be used should be monitored for changes in INR. Moxifloxacin does not significantly affect low-dose oral contraceptive or digoxin pharmacokinetics (Guay 2005). Unlike the case with ciprofloxacin, norfloxacin, levofloxacin, and gatifloxacin, probenecid does not significantly alter the systemic pharmacokinetics of moxifloxacin (Guay 2005).

Like all quinolones, moxifloxacin is susceptible to interactions with multivalent cations, wherein the reductions in bioavailability may be clinically-relevant and lead to a loss of therapeutic benefit. For example, calcium carbonate or calcium lactate-gluconate given immediately before and 12 h and 24 h after single-dose moxifloxacin resulted in a mean 15% reduction in $C_{\text{max}}$ ($p \leq 0.05$) and a mean 2% reduction in AUC ($p=\text{NS}$) (Guay 2005). Simultaneous administration of single-dose ferrous sulfate lead to mean reductions of 59 and 39% in single-dose moxifloxacin $C_{\text{max}}$ and AUC, respectively (both, $p \leq 0.05$) (Guay 2005). Single-dose magnesium-aluminum antacid administered simultaneously with single-dose moxifloxacin resulted in mean 61% and 59% reductions in $C_{\text{max}}$ and AUC, respectively (both, $p \leq 0.05$). When the antacid administration was delayed until 2 h after moxifloxacin administration, the mean 7% reduction in $C_{\text{max}}$ was non-significant but the mean 26% reduction in AUC was significant ($p \leq 0.05$). Even administering the antacid 4 h before moxifloxacin administration still resulted in a significant reduction in quinolone AUC (mean 23%, $p \leq 0.05$) although the mean 1% fall in $C_{\text{max}}$ was not (Guay 2005). Sucralfate administered simultaneously with and then 5 h, 10 h, 15 h, and 24 h following single-dose moxifloxacin administration resulted in mean 71% and 60% reductions in quinolone $C_{\text{max}}$ and AUC, respectively (both, $p \leq 0.05$) (Guay 2005). Ranitidine, a histamine-2 receptor antagonist, does not interact with moxifloxacin (2 studies) and can be recommended as a noninteracting antiulcer therapy alternative to sucralfate and antacids (Guay 2005).

Pharmacodynamic drug–drug interactions

The only potentially clinically-relevant pharmacodynamic drug–drug interaction with moxifloxacin involves additive electrophysiological effects with other drugs that can also prolong the QTc interval on the electrocardiogram (Table 5) (Guay 2005). Drugs which prolong cardiac repolarization may, on rare occasions, be associated with the development of polymorphous ventricular tachycardia (“torsades de pointes”) which, in turn, may degenerate into ventricular fibrillation. Quinolones cause a drug-specific, dose-dependent prolongation of QTc interval by inhibiting outward potassium currents in myocytes. In numerous in vitro models examining the mechanism(s) underlying this arrhythmogenic effect, sparflaxacin has been more potent than moxifloxacin (= grepafloxacin) which, in turn, has been more potent than the other tested quinolones (Guay 2005). In in vivo (animal) models, sparflaxacin again was most potent followed by the trio of moxifloxacin–gatifloxacin–grepafloxacin (latter agent has been withdrawn from the market) (Guay 2005). Concentration-response relationships have been demonstrated in both in vitro and in vivo preclinical models (Chen et al 2005).

In one healthy volunteer study, single 400 mg and 800 mg oral doses of moxifloxacin caused mean ± SD 4.0% ± 5.1% and 4.5% ± 3.8% QTc interval prolongation at rest compared with baseline, respectively (both, $p \leq 0.05$). Significant QTc interval prolongation occurred at all heart rates and across the entire RR interval range (400–1000 msec). There were no gender-dependent differences in results. The correlation of moxifloxacin plasma concentrations and QT interval was significant but weak ($r=0.35$) (Guay 2005).

Only two comparative studies of the effect of quinolones on QTc intervals have been published. In the first, single

Table 5 Drugs prolonging the QT interval that may potentially interact pharmacodynamically with moxifloxacin. Modified from Guay 2005

| Drug | Description |
|------|-------------|
| Amiodarone | (rare) |
| Bepridil |  |
| β-blockers | (rare) |
| Chloroquine |  |
| Dofetilide |  |
| Disopyramide |  |
| Encainide |  |
| Flecaïnine |  |
| Halofantrine |  |
| Ibutilide |  |
| Lidocaine | (rare) |
| Lidoflazine |  |
| Macrolides (erythromycin, clarithromycin, spiramycin) |  |
| Mexiletine | (rare) |
| Pentamidine |  |
| Phenothiazines |  |
| Procainamide |  |
| Quinidine |  |
| Sotalol |  |
| Tricyclic antidepressants |  |

Therapeutics and Clinical Risk Management 2006:2(4)
oral doses of levofloxacin (1000 mg), ciprofloxacin (1500 mg) and moxifloxacin (800 mg) were evaluated in a placebo-controlled, crossover trial in healthy volunteers. Mean QT and QTc interval prolongation was significantly greater for moxifloxacin compared with placebo for all end points, but it was generally not for the other two quinolones. The proportion of subjects with QTc interval prolongation of 30 msec. or higher was greater with moxifloxacin (72%–81%) compared with levofloxacin (33%–38%) and ciprofloxacin (34%–40%) (Guay 2005). In the second, 13 healthy volunteers received three 7-day regimens in random order: ciprofloxacin 500 mg twice daily, levofloxacin 500 mg once daily, and moxifloxacin 400 mg once daily. Washout periods between treatments were one week in length. Twelve-lead electrocardiograms were obtained before, 2 h after the first dose, and at the end of each regimen.

The proportion of subjects with QTc interval prolongation of 30 msec. or higher was greater with moxifloxacin (72%–81%) compared with levofloxacin (33%–38%) and ciprofloxacin (34%–40%) (Guay 2005). In the second, 13 healthy volunteers received three 7-day regimens in random order: ciprofloxacin 500 mg twice daily, levofloxacin 500 mg once daily, and moxifloxacin 400 mg once daily. Washout periods between treatments were one week in length. Twelve-lead electrocardiograms were obtained before, 2 h after the first dose, and at the end of each regimen. At the end of 7 days, moxifloxacin prolonged QTc by a mean of 6 msec compared with baseline (p=0.022) and a mean of 11 msec from the 2 h baseline value (p=0.003). Ciprofloxacin and levofloxacin had no significant effect on QTc. No quinolone had a significant effect on QTc. No quinolone had a significant effect on QT dispersion, a parameter felt to be a more selective marker for risk of polymorphous ventricular tachycardia (Tsikouris et al 2006).

Further studies of QT dispersion, especially in patients receiving quinolone therapy, with/without concurrent use of other drugs which also prolong QTc, are warranted.

The lack of multiple dose studies and well-done epidemiologic studies do not allow an assessment of the clinical relevance of the above-cited findings. In a recent randomized trial comparing the cardiac safety of IV/oral moxifloxacin and levofloxacin in elderly patients hospitalized for community-acquired pneumonia, the two agents had similar cardiac rhythm safety profiles (Morganroth et al 2005). However, it is prudent to use caution when using moxifloxacin (and other quinolones) in patients already receiving potentially arrhythmogenic drugs (Table 5) (Guay 2005). Similarly, caution is warranted when use is contemplated in patients with abnormal pretreatment QTc intervals, electrolyte abnormalities (especially hypokalemia, hypomagnesemia, rarely hypocalcemia), starvation/liquid protein fast diets, and prior/current history of coronary artery disease or arrhythmias.

**Dosing**

Moxifloxacin is available as 400 mg oral tablets and premixed moxifloxacin 400 mg in 250 mL 0.8% sodium chloride IV bags (Anonymous 2005). For SSSIs, the recommended daily dose is 400 mg and the recommended durations of therapy are 7 days (uncomplicated infections) and 7–21 days (complicated infections). Oral doses of moxifloxacin should be administered at least 4 h before or 8 h after magnesium/aluminum antacids, sucralfate, metal cations (eg, iron), multivitamin + mineral supplements (especially with zinc), and didenosine chewable/buffered tablets or pediatric powder for solution (Anonymous 2005). No dosage adjustment is needed with any level of renal impairment or mild or moderate (Child-Pugh Class A or B) hepatic impairment (Anonymous 2005). In severe (Child-Pugh Class C) hepatic impairment, there are no data to guide the clinician (Anonymous 2005).

**Conclusions**

Optimal therapy for SSSIs requires careful patient evaluation, including obtaining a thorough medical and social history, performing a meticulous examination of the lesion(s), and examination of Gram-stained smears of lesion exudates. Early empirical antimicrobial therapy is the next step after obtaining culture specimens, with subsequent tailoring of therapy based on culture and sensitivity results. Local measures, including debridement, are important adjuncts to antimicrobial therapy. Selection of empiric therapy for SSSIs depends on a number of factors, including type of infection (uncomplicated vs complicated), location of acquisition (community versus hospital), and local sensitivity patterns for the commonest dermatologic pathogens.

Older quinolones have been demonstrated to be efficacious in the treatment of uncomplicated and complicated SSSIs over the past 20 years (Blondeau 2002; Sable and Murakawa 2003). In addition, more limited data support the efficacy of the newer quinolones in the treatment of uncomplicated SSSIs (gatifloxacin, levofloxacin 500 mg/d, and moxifloxacin) (Leal del Rosal, Fabian, et al 1999; Leal de Rosal, Martinez, et al 1999; Parish et al 2000; Raghavan and Linden 2004). To these data may be added those documenting the efficacy of high-dose levofloxacin (750 mg/d) and moxifloxacin in the treatment of complicated SSSIs (Raghavan and Linden 2004; Anonymous 2005).

What have other reviews recently said regarding the role of quinolones in the treatment of SSSIs? In a recent review of the diagnosis and treatment of facial bite wounds, moxifloxacin was felt to be a reasonable monotherapy for infected human facial bite wounds, especially in patients who are penicillin-allergic. The suggested duration of a prophylactic regimen ranged from 3–5 days (10–14 days if bone was involved). For treatment, if bones or joints were involved.

**Optimizing therapy for SSSIs requires careful patient evaluation, including obtaining a thorough medical and social history, performing a meticulous examination of the lesion(s), and examination of Gram-stained smears of lesion exudates. Early empirical antimicrobial therapy is the next step after obtaining culture specimens, with subsequent tailoring of therapy based on culture and sensitivity results. Local measures, including debridement, are important adjuncts to antimicrobial therapy. Selection of empiric therapy for SSSIs depends on a number of factors, including type of infection (uncomplicated vs complicated), location of acquisition (community versus hospital), and local sensitivity patterns for the commonest dermatologic pathogens.**

**Older quinolones have been demonstrated to be efficacious in the treatment of uncomplicated and complicated SSSIs over the past 20 years (Blondeau 2002; Sable and Murakawa 2003). In addition, more limited data support the efficacy of the newer quinolones in the treatment of uncomplicated SSSIs (gatifloxacin, levofloxacin 500 mg/d, and moxifloxacin) (Leal del Rosal, Fabian, et al 1999; Leal de Rosal, Martinez, et al 1999; Parish et al 2000; Raghavan and Linden 2004). To these data may be added those documenting the efficacy of high-dose levofloxacin (750 mg/d) and moxifloxacin in the treatment of complicated SSSIs (Raghavan and Linden 2004; Anonymous 2005).**

**What have other reviews recently said regarding the role of quinolones in the treatment of SSSIs? In a recent review of the diagnosis and treatment of facial bite wounds, moxifloxacin was felt to be a reasonable monotherapy for infected human facial bite wounds, especially in patients who are penicillin-allergic. The suggested duration of a prophylactic regimen ranged from 3–5 days (10–14 days if bone was involved). For treatment, if bones or joints were involved.
involved, a duration of 21+ days was recommended (Stefanopoulos and Tarantzopoulou 2005).

In a review of the role of quinolones in the treatment of SSSIs, Blondeau felt that both older and newer quinolones had roles to play. The older ciprofloxacin-type quinolones were recommended only in SSSIs where Gram-negative aerobic bacilli were known pathogens, adding clindamycin or metronidazole in suspected mixed infections. The newer quinolones (including moxifloxacin) were recommended in SSSIs where non-pseudomonal Gram-negative aerobic bacilli were known pathogens, where there was a mixed infection with anaerobes within the quinolone’s spectrum of activity, where non-methicillin-resistant S. aureus gram-positive aerobes were involved, and where Gram-positive and Gram-negative aerobic pathogens were coexisting (Blondeau 2002).

The first organization-based guidelines for the diagnosis and management of SSSIs were published by IDSA in November 2005 (Stevens et al 2005). Quinolones are mentioned in the context of several general and organism-specific infections. Quinolones are one of many empirical choices in human and animal bite wounds, especially in patients with severe penicillin allergies. Ciprofloxacin, gatifloxacin, and moxifloxacin with/without clindamycin or metronidazole are those specifically mentioned. Again, quinolones are one of many empirical choices in SSSIs in the immunocompromised host. A quinolone (probably ciprofloxacin) plus an extended-spectrum β-lactam is the specific quinolone mentioned. Quinolones are one of several choices for the empiric management of each of three defined types of surgical wound infections. In community-acquired mixed necrotizing fasciitis, one option is a combination of ciprofloxacin plus a β-lactam-β-lactamase inhibitor. In SSSIs due to community-acquired MRSA, the newer quinolone group (including moxifloxacin) is one option (author’s comment: based on 20 years of experience with quinolones in infections due to MRSA, the likelihood of the development of resistance to quinolones during such use is quite high. caution is warranted). Lastly, in infected wounds after intestinal or genital tract surgeries, a combination of a quinolone plus one of clindamycin/metronidazole/chloramphenicol/β-lactam-β-lactamase inhibitor is one option. Quinolones are mentioned in the context of the patient with severe penicillin allergies. In cutaneous anthrax, ciprofloxacin is the drug-of-choice (newer quinolones are also considered likely effective). In erysipeloid, quinolones are options only in patients with severe penicillin allergies. Lastly, among many options, levofloxacin and ciprofloxacin are considered options for tularemia but only in mild to moderate illness.

Evolving resistance trends, especially amongst staphylococci and enterococci, and sporadic intolerance to conventional β-lactam therapy have led to the need for novel options with proven efficacy and tolerability. Moxifloxacin is comparable in both efficacy and tolerability with conventional agents for SSSIs and is also effective against many organisms resistant to these agents (exception: methicillin-resistant staphylococci). It also possesses activity against atypical mycobacteria associated with SSSIs (moxifloxacin may develop into a first-line therapy for these types of SSSIs but much work remains to be done before this can be recommended). Despite its proven activity against dermatologic pathogens, one could argue that its use be carefully considered and, in general, restricted to serious, life-threatening infections caused by resistant pathogens or those patients with serious intolerances to conventional therapy. In this way, the development and progression of resistance might be blunted and its “lifespan” as an antimicrobial for dermatologic infections prolonged.

References
Ackermann G, Schumann R, Pless B, et al. 2000. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis, 19:228-32.
Alcaide F, Calatayud L, Santin M, et al. 2004. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother, 48:4562-5.
Aldridge KE, Ashcroft DS. 1997. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother, 41:709-11.
Amabile-Cuevas CF, Hermida-Escobedo C, Vivar R. 2001. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes. Clin Infect Dis, 32(Suppl 1):S30-2.
Andriele VT, Haverson DC, Choudhri SH. 2005. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Safety, 28:443-52.
Anonymous. 2005. Avelox® (moxifloxacin) product information. Bayer HealthCare, West Haven, CT, June 2005.
Aubry A, Jarlier V, Escalonot S, et al. 2000. Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob Agents Chemother, 44:3133-6.
Ball P, Stahlmann R, Kubin R, et al. 2004. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther, 26:940-50.
Ballow C, Lettieri J, Agarwal V, et al. 1999. Absolute bioavailability of moxifloxacin. Clin Ther, 21:513-22.
Barry AL, Fuchs PC, Brown SD. 1999. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. Eur J Clin Microbiol Infect Dis, 18:305-9.
Bauerfeind A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother, 40:639-51.
Betriu C, Gomez M, Palau ML, et al. 1999. Activities of new antimicrobial agents (trotavloxacin, moxifloxacin, sanfetrinem, and quinupristindalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. *Antimicrob Agents Chemother*, 43:2320-2.

Betriu C, Rodriguez-Avial I, Gomez M, et al. 2005. Changing patterns of fluoroquinolone resistance among *Bacteroides fragilis* group organisms over a 6-year period (1997-2002). *Diag Microbiol Infect Dis*, 53:221-3.

Biedenbach DJ, Toleman MA, Walsh TR, et al. 2006. Characterization of fluoroquinolone-resistant β-hemolytic *Streptococcus* spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant *Streptococcus dysgalactiae* subspecies *equisimilis*: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). *Diag Microbiol Infect Dis*, 55:119-27.

Blondeau JM, Laskowski R, Bjarnason J, et al. 2000. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 gram-negative and gram-positive organisms. *Int J Antimicrob Agents*, 14:45-50.

Blondeau JM. 2002. The role of fluoroquinolones in skin and skin structure infections. *Am J Dermatol*, 3:37-46.

Bogdanovich T, Esel D, Kelly LM, et al. 2005. Antistaphylococcal activity of DX-169, a new des-F(6)-quinolone, compared with those of other agents. *Antimicrob Agents Chemother*, 49:3335-32.

Boswell FJ, Andrews JM, Wise R. 1997. Pharmacodynamic properties of Bay 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. *Antimicrob Agents Chemother*, 41:1377-9.

Bowker KE, Noel AR, MacGowan AP. 2003. In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. *Int J Antimicrob Agents*, 22:557-61.

Braback M, Riesbeck K, Forsgren A. 2002. Susceptibilities of *Mycobacterium marinum* to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared with its susceptibilities to reference macrolides and quinolones. *Antimicrob Agents Chemother*, 46:1114-16.

Burkhardt O, Borner K, Stass H, et al. 2002. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. *Scand J Infect Dis*, 34:898-903.

Burkhardt O, Stass H, Thus U, et al. 2005. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. *Clin Pharmacokinet*, 44:969-76.

Chen X, Cass JD, Bradley JA, et al. 2005. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. *Br J Pharmacol*, 146:792-9.

Credito KL, Jacobs MR, Applebaum PC. 2003. Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents. *Antimicrob Agents Chemother*, 47:1399-402.

Critchley IA, Sahm DF, Thornberry C, et al. 2002. Antimicrobial susceptibilities of *Streptococcus pyogenes* isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. *Diag Microbiol Infect Dis*, 42:129-35.

Dalhoff A, Petersen U, Endermann R. 1996. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. *Chemotherapy*, 42:410-25.

Dalhoff A, Schubert S, Ullmann U. 2005. Effect of pH on the *in vitro* activity of and propensity for the emergence of resistance to fluoroquinolones, macrolides, and a ketolide. *Infection*, 33(suppl 2):36-43.

Dan M, Keynan O, Feldbrin Z, et al. 2004. Concentrations of moxifloxacin in serum and synovial fluid, and *ex vivo* bactericidal activity against arthritis-causing pathogens. *Diag Microbiol Infect Dis*, 48:283-6.

Draenert R, Kunzelmann M, Roggenkamp A, et al. 2005. Infected cat-bite wound treated successfully with moxifloxacin after failure of parenteral cefuroxime and ciprofloxacin. *Eur J Clin Microbiol Infect Dis*, 24:288-90.

Duncan K, Barry CE 3rd. 2004. Prospects for new antitubercular drugs. *Curr Opin Microbiol*, 7:460-5.

Edlund C, Sabouri S, Nord CE. 1998. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. *Eur J Clin Microbiol Infect Dis*, 17:193-5.

Edmiston CE, Krepel CJ, Seabrook GR, et al. 2004. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. *Antimicrob Agents Chemother*, 48:1012-16.

Edmiston CE, Krepel CJ, Kehl KS, et al. 2005. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic, and otolaryngologic surgical patients. *J Antimicrob Chemother*, 56:872-8.

Ednie LM, Rattan A, Jacobs MR, et al. 2003. Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. *Antimicrob Agents Chemother*, 47:1143-7.

Elbe DH, Chang SW. 2005. Moxifloxacin-warfarin interaction: a series of five case reports. *Ann Pharmacother*, 39:361-4.

Esposito S, Noviello S, Ianniello F. 2000. Bactericidal activity of moxifloxacin compared with grepafloxacin and clarithromycin against *Streptococcus pneumoniae* and *Streptococcus pyogenes* investigated using an in vitro pharmacodynamic model. *J Chemother*, 12:475-81.

Fass RJ. 1997. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. *Antimicrob Agents Chemother*, 41:1818-24.

Fuhrmann V, Schenk P, Jaeger W, et al. 2004. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous hemodiafiltration. *J Antimicrob Chemother*, 54:780-4.

Fung-Tome JC, Minassian B, Kolek B, et al. 2000. Antibacterial spectrum of a novel des-fluoro(6)quinolone, BMS-284756. *Antimicrob Agents Chemother*, 44:3351-6.

Gavin JR 3rd, Kubin R, Choudhri S, et al. 2004. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. *Drug Safety*, 27:671-86.

Gillespie SH, Billington O. 1999. Activity of moxifloxacin against mycobacteria. *J Antimicrob Chemother*, 44:393-5.

Giordano P, Song J, Pentel P, et al. 2005. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. *J Int Antimicrob Agents*, 26:357-65.

Golan Y, McDermott LA, Jacobus NV, et al. 2003. Emergence of fluoroquinolone resistance among *Bacteroides* species. *J Antimicrob Chemother*, 52:208-13.

Goldstein EJ, Citron DM, Hudspeth M, et al. 1997. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared with the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. *Antimicrob Agents Chemother*, 41:1552-7.

Goldstein EJ, Citron DM, Merriam CV, et al. 2000. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. *Antimicrob Agents Chemother*, 44:2747-51.

Goldstein EJ, Citron DM, Merriam CV, et al. 2002. In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine *Pasteurella* species. *Antimicrob Agents Chemother*, 46:3068-70.

Goldstein EJ, Citron DM, Warren YA, et al. 2006. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. *Antimicrob Agents Chemother*, 50:148-55.

Guay DRP. 2005. Chapter 8. Quinolones. In: Piscitelli SC, Rodvold KA (eds). Infectious disease: drug interactions in infectious diseases. 2nd ed. Totowa, NJ: Humana Pr. p 215-54.

Hardy D, Amsterdam D, Mandell LA, et al. 2000. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparflafoxin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. *Antimicrob Agents Chemother*, 44:802-5.
Hedberg M, Nord CE, ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. 2003. Antimicrobial susceptibility of *Bacteroides fragilis* group isolates in Europe. *Clin Microbiol Infect*, 9:475-88.

Hermens ED, Hovde LB, Sprandell KA, et al. 2005. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of *Escherichia coli* and *Bacteroides fragilis* in an in vitro pharmacodynamic model. *Antimicrob Agents Chemother*, 49:685-9.

Hoellman DB, Kelly LM, Jacobs MR, et al. 2001. Comparative antianaerobic activity of BMS 284756. *Antimicrob Agents Chemother*, 45:589-92.

Hooogkamp-Korstanje JA, Roelofs-Willemse J. 2000. Comparative in vitro activity of moxifloxacin against gram-positive clinical isolates. *J Antimicrob Chemother*, 45:31-9.

Jacobs MR, Bajaksouzian S, Windau A, et al. 2004. In vitro activity of the newer quinolone WCK 771 against staphylococci. *Antimicrob Agents Chemother*, 48:3338-42.

Ji B, Grosset J. 2000. Combination of rifampentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. *Leprosy Rep*, 71(Suppl):S81-7.

Joukhadar C, Teng LJ, Lee CM et al. 2003. Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of *Streptococcus pyogenes*: SMART Program 2001 Data. *Antimicrob Agents Chemother*, 47:2152-7.

Ince D, Zhang X, Hooper DC. 2003. Activity of and resistance to moxifloxacin in *Staphylococcus aureus*. *Antimicrob Agents Chemother*, 47:1410-15.

Jacobs MR, Bajaksouzian S, Windau A, et al. 2004. In vitro activity of the new quinolone WCK 771 against staphylococci. *Antimicrob Agents Chemother*, 48:3338-42.

Kalteis T, Beckmann J, Schroder H-J, et al. 2006a. Moxifloxacin superior to vancomycin for treatment of bone infections - a study in rats. *Acta Orthoped.*, 77:315-19.

Kalteis T, Beckmann J, Schroder H-J, et al. 2006b. Treatment of implant-associated infections with moxifloxacin: an animal study. *Int J Antimicrob Agents*, 27:444-8.

Labombardi VJ, Shastry L, Tischler H. 2005. *Mycobacterium thermoresistibile* infection following knee-replacement surgery. *J Clin Microbiol*, 43:5393-5.

Leal del Rosal P, Fabian G, Vick-Fragoso R, et al. 1999. Efficacy and safety of moxifloxacin (MXF) vs. cephalxin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structure infections (uSSSI) [abstract]. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, Sept. 26–29. 1076.

Leal del Rosal P, Martinez R, Fabian G, et al. 1999. Efficacy and safety of moxifloxacin vs. cephalxin in the treatment of mild to moderate uncomplicated skin and skin structure infections (uSSSI). *J Antimicrob Chemother*, 44(suppl A):148. P493.

Lemmen SW, Hafner H, Klik S, et al. 2003. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Escherichia coli* and *Klebsiella pneumoniae*. *Chemotherapy*, 49:33-5.

Lettieri J, Vargas R, Agarwal V, et al. 2001. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers. *Clin Pharmacokinet*, 40(Suppl 1):19-25.

Lion C, Conroy MC, Carpenter AM, et al. 2006. Antimicrobial susceptibilities of *P Pasteurella* strains isolated from humans. *Int J Antimicrob Agents*, 27:290-3.

Lister PD. 2001. Pharmacodynamics of moxifloxacin and levofloxacin against *Staphylococcus aureus* and *Staphylococcus epidermidis* in an in vitro pharmacodynamic model. *Clin Infect Dis*, 32(Suppl 1):S33-8.

Lubasch A, Keller I, Borner K, et al. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. *Antimicrob Agents Chemother*, 44:2600-3.

MacGowan AP, Bowker KE, Holt HA, et al. 1997. Bay 12-8039, a new 8-methoxy-quinolone: comparative *in-vitro* activity with nine other antimicrobials against anaerobic bacteria. *J Antimicrob Chemother*, 40:503-9.

Malathum K, Singh KV, Murray BE. 1999. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria. *Diagn Microbiol Infect Dis*, 35:127-33.

Malinconico L, Ghebregzabher M, Moretti MV, et al. 2006. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. *J Antimicrob Chemother*, 57:950-4.

Man I, Murphy J, Ferguson J. 1999. Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. *J Antimicrob Chemother*, 43(Suppl B):77-82.

Mandell GL, Coleman E. 2001. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. *Antimicrob Agents Chemother*, 45:1794-8.

Militovíc D, Schmitz FJ, Brisse S, et al. 2000. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. *Antimicrob Agents Chemother*, 44:1102-7.

Mitscher L. 2005. Bacterial topoisomerase inhibitors: quinolone and pyrrole antibacterial agents. *Chem Rev*, 105:559-72.

Morganweck J, DiMarco JD, Anzueto A, et al; CAPRIE Study Group. 2005. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs. levofloxacin in elderly patients hospitalized with community-acquired pneumonia. *Chest*, 128:3398-406.

Muller M, Stass H, Brunner M, et al. 1999. Penetration of moxifloxacin into peripheral compartments in humans. *Antimicrob Agents Chemother*, 43:2345-9.

Noel AR, Bowker KN, MacGowan AP. 2005. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. *Antimicrob Agents Chemother*, 49:4234-9.

Nori S, Nebesio C, Brashear R, et al. 2004. Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure (letter). *Arch Dermatol*, 140:1537-8.

Noviello S, Ianniello F, Leone S, et al. 2003. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against *Staphylococcus aureus*, *Streptococcus pyogenes* and respiratory pathogens. *J Antimicrob Chemother*, 52:869-71.

Odenholt I, Lowdin E, Gustafsson I, et al. 2002. Pharmacodynamics of moxifloxacin against *Streptococcus pyogenes* in an in vitro kinetic model. *Antimicrob Agents Chemother*, 46:2046-8.

Parish LC, Routh HB, Miskin B, et al. 2000. Moxifloxacin versus cephalxin in the treatment of uncomplicated skin infections. *Int J Clin Pract*, 54:497-503.

Park-Wyllie LY, Juurlink DN, Kopp A, et al. 2006. Outpatient gatifloxacin therapy and dysglycemia in older adults. *N Engl J Med*, 354:1352-61.

Patel MV, De Souza NJ, Gupta SV, et al. 2004. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. *Antimicrob Agents Chemother*, 48:4754-61.

Pea F, Pavan F, Lugatti E, et al. 2006. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. *Clin Pharmacokinet*, 45:287-95.

Perez-Giraldo C, Gonzalez-Velasco C, Sanchez-Silos RM, et al. 2004. Moxifloxacin and biofilm production by coagulase-negative *staphylococci*. *Chemotherapy*, 50:101-4.

Peric M, Jacobs MR, Appelbaum PC. 2004. Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared with those of nine other agents. *Antimicrob Agents Chemother*, 48:3188-92.

Raghavan M, Linden PK. 2004. Newer treatment options for skin and soft tissue infections. *Drugs*, 64:1621-42.

Rodriguez Diaz JC, Lopez M, Ruiz M, et al. 2003. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. *Int J Antimicrob Agents*, 21:585-8.
